ArticleEuropean journal of human genetics : EJHG2014
WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.
Article in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Measurement characteristics of WHODAS 2.0 and WHODAS-Child: a systematic review of global psychometric studies in specific populations since 2010.Frontiers in psychiatry · 2026Pooled it
- Assessment by proxy of the SF-36 and WHO-DAS 2.0. A systematic review.Journal of rehabilitation medicine · 2023Pooled it
- Huntington Study Group's Neuropsychology Working Group: Implementing Non-Motor Diagnostic Criteria.Movement disorders clinical practice · 2023Review
- Health related quality of life among people with mental illness: The role of socio-clinical characteristics and level of functional disability.Frontiers in public health · 2023Article
- Clinical Decision Trees to Guide Physical Therapy Management of Persons with Huntington's Disease.Journal of Huntington's disease · 2022Review
- Psychometric Properties and Validation of the Polish Version of the 12-Item World Health Organization Disability Assessment Schedule 2.0 in Patients with Huntington's Disease.Journal of clinical medicine · 2021Article
- The 12 items Amharic version WHODAS-2 showed cultural adaptation and used to measure disability among road traffic trauma victims in Ethiopia.BMC psychology · 2021Article
- Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease.Frontiers in neurology · 2021Article
- Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- Validation of the World Health Organization Disability Assessment Schedule 2.0 among older adults in an Asian country.Singapore medical journal · 2020Article
- Proxy WHO Disability Assessment Schedule 2.0 Is Clinically Useful for Assessing Psychosocial Functioning in Severe Mental Illness.Frontiers in psychiatry · 2020Article
- Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.Journal of Huntington's disease · 2019Article
- A Novel Ecological Approach Reveals Early Executive Function Impairments in Huntington's Disease.Frontiers in psychology · 2019Article
- Functional impairment among people diagnosed with depression in primary healthcare in rural Ethiopia: a comparative cross-sectional study.International journal of mental health systems · 2019Article
- Article
- Functional impairment among people with severe and enduring mental disorder in rural Ethiopia: a cross-sectional study.Social psychiatry and psychiatric epidemiology · 2018Article
- Allocation of forest biomass across broad precipitation gradients in China's forests.Scientific reports · 2018Article
- Understanding the need for assistance with survey completion in people with Huntington disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Article
- Validation of the World Health Organization Disability Assessment Schedule in people with severe mental disorders in rural Ethiopia.Health and quality of life outcomes · 2017Article
- Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD.Journal of Huntington's disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Clinical trials to improve day-to-day function in Huntington disease (HD) require accurate outcome measures. The DSM-5 recommends the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 for use in neuropsychiatric disorders. The DSM-5 also states proxy measures may be useful when cognitive function may be impaired. We tested WHODAS participant and companion ratings for differences in baseline and longitudinal function in three prodromal HD groups and a control group. Participants with prodromal HD were stratified by disease progression (low, medium, and high disease burden) based on their cytosine-adenine-guanine (CAG)-age product (CAP) score. Participant (N=726) and companion (N=630) WHODAS scores were examined for group differences, and for participant versus companion differences using linear mixed effects regression and Akaike's information criterion to test model fit. We also compared WHODAS with the Total Functional Capacity (TFC) scale. At baseline, functioning on the WHODAS was rated worse by participants in the high group and companions compared with controls. For longitudinal changes, companions reported functional decline over time in the medium and high groups. In simultaneous analysis, participant and companion longitudinal trajectories showed divergence in the high group, suggesting reduced validity of self-report. The WHODAS showed greater longitudinal difference than the TFC in the medium group relative to controls, whereas the TFC showed greater longitudinal difference than WHODAS in the high group. Results suggest the WHODAS can identify baseline and longitudinal differences in prodromal HD and may be useful in HD clinical trials. Companions may provide more accurate data as the disease progresses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.